US Patent

US10030005 — Inhibitors of RET

Method of Use · Assigned to Blueprint Medicines Corp · Expires 2036-11-01 · 10y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects compounds that inhibit the RET protein and its resistant mutants, as well as methods of using these compounds.

USPTO Abstract

Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

Drugs covered by this patent

Gavreto (PRALSETINIB) · Rigel Pharms

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2952`	—	Gavreto

Patent Metadata

Patent number: US10030005
Jurisdiction: US
Classification: Method of Use
Expires: 2036-11-01
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Blueprint Medicines Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.